Please ensure Javascript is enabled for purposes of website accessibility

Biogen Reports First-Quarter Results, Shares Plunge 9.4%

By Prosper Junior Bakiny - Apr 22, 2020 at 4:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company announced that its FDA filing of aducanumab, a potential treatment for Alzheimer’s disease, will be delayed.

Biogen (BIIB -1.23%) released its first-quarter earnings report before the market opened on Wednesday, reporting $3.5 billion in revenue, a 1% year-over-year increase. Sales of the multiple sclerosis drug Tecfidera, which is the biotech company's best-selling product, grew 10% to $1.1 billion. And Spinraza, its treatment for spinal muscular atrophy, recorded revenue of $565 million, up 9% compared to the prior-year quarter. 

Biogen's revenue got a $100 million boost as a result of accelerated sales propelled by the COVID-19 pandemic. The company's GAAP net income was $1.4 billion, or $8.08 per share basis. Its net income decreased by less than 1% compared to the year-ago period, while its earnings per share increased by 13%.

Doctor with a confused facial expression and his hands raised in the air.

Image Source: Getty Images.

However, arguably the most crucial part of Biogen's report was an update regarding its potential treatment for Alzheimer's disease, aducanumab, which the company is developing in collaboration with Esai (ESALY -0.24%). In March 2019, Biogen discontinued the development of aducanumab because it had not demonstrated  effectiveness against the symptoms of Alzheimer's in a phase 3 clinical trial. However, in October, Biogen announced that it would seek regulatory approval for aducanumab after all. 

According to the company, a more extensive data set revealed that Alzheimer's patients treated with aducanumab experienced "significant benefits on measures of cognition and function." Biogen had planned to submit aducanumab to the Food and Drug Administration for review in early 2020.

Now, the biotech giant says it expects to complete its FDA filing for aducanumab in the third quarter of 2020. Biogen's stock slid by about 9.4% on Wednesday, likely in reaction to the delay.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Biogen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Biogen Inc. Stock Quote
Biogen Inc.
$219.64 (-1.23%) $-2.74
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
$46.45 (-0.24%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.